Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1-, E3-, polymerase-] adenovirus vector expressing human apoE

被引:36
作者
Harris, JD
Graham, IR
Schepelmann, S
Stannard, AK
Roberts, ML
Hodges, BL
Hill, VJ
Amalfitano, A
Hassall, DG
Owen, JS
Dickson, G [1 ]
机构
[1] Univ London, Ctr Biomed Sci, Sch Biol Sci, Egham TW20 0EX, Surrey, England
[2] UCL Royal Free & Univ Coll Med Sch, Dept Med, London NW3 2PF, England
[3] Duke Univ, Med Ctr, Dept Pediat, Div Genet, Durham, NC 27710 USA
[4] GlaxoSmithKline Inc, Res & Dev, Med Res Ctr, Stevenage SG1 2NY, Herts, England
关键词
D O I
10.1093/hmg/11.1.43
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Apolipoprotein E (apoE) is a 34 kDa glycoprotein with multiple actions that help protect against the development of atherosclerosis. Here, we have assessed the atheroprotective potential of an [E1(-), E3(-), polymerase(-)] adenovirus vector expressing human apoE, comparing intramuscular and intravenous (liver-directed) injections in hypercholesterolaemic apoE-deficient mice (apoE(-/-)). Intramuscular injections resulted in low expression of apoE and afforded no protection against atherogenesis. In contrast, 3 and 7 days after intravenous injections into young (6-8-week-old) apoE(-/-) mice, plasma levels of apoE were elevated and were accompanied by reductions in plasma cholesterol and normalization of lipoprotein profiles. Thereafter, plasma apoE was still detectable up to day 70, but gradually declined, although no humoral immune response was evoked, and there was a return to dyslipoproteinaemia. High levels of the vector genome were still present in livers of treated animals at 70 days, implying that decrease in apoE expression was due to cellular shutdown of the cytomegalovirus promoter. Importantly, liver-directed apoE gene transfer to these young mice retarded progression of atherosclerosis by 38% (treated, 8.21 +/- 1.05%; untreated, 13.26 +/- 0.98%, P < 0.05), during the 70 day study period. Moreover, when 10-month-old apoE(-/-) mice with advanced atherosclerosis were treated with the adenovirus vector, there was clear regression of aortic lesion area by 1 month [24.3 +/- 1.7% compared to 40.7 +/- 2.6% in baseline controls (P < 0.002)]. We conclude that the stability of the adenovirus vector genome in the livers of intravenously treated animals provides an ideal platform to evaluate liver-specific promoters for sustained transgene expression and control of atherosclerotic lesion pathology.
引用
收藏
页码:43 / 58
页数:16
相关论文
共 68 条
  • [51] Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA
    Rinaldi, M
    Catapano, AL
    Parrella, P
    Ciafrè, SA
    Signori, E
    Seripa, D
    Uboldi, P
    Antonini, R
    Ricci, G
    Farace, MG
    Fazio, VM
    [J]. GENE THERAPY, 2000, 7 (21) : 1795 - 1801
  • [52] FAMILIAL APOLIPOPROTEIN-E DEFICIENCY
    SCHAEFER, EJ
    GREGG, RE
    GHISELLI, G
    FORTE, TM
    ORDOVAS, JM
    ZECH, LA
    BREWER, HB
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (05) : 1206 - 1219
  • [53] SHIH W, 2000, ARTERIOSCLER THROMB, V20, P2261
  • [54] ADENOVIRUS-MEDIATED EXPRESSION OF THERAPEUTIC PLASMA-LEVELS OF HUMAN FACTOR-IX IN MICE
    SMITH, TAG
    MEHAFFEY, MG
    KAYDA, DB
    SAUNDERS, JM
    YEI, S
    TRAPNELL, BC
    MCCLELLAND, A
    KALEKO, M
    [J]. NATURE GENETICS, 1993, 5 (04) : 397 - 402
  • [55] PHENOTYPIC CORRECTION OF HYPERCHOLESTEROLEMIA IS APOE-DEFICIENT MICE BY ADENOVIRUS-MEDIATED IN-VIVO GENE-TRANSFER
    STEVENSON, SC
    MARSHALLNEFF, J
    TENG, B
    LEE, CB
    ROY, S
    MCCLELLAND, A
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (04) : 479 - 484
  • [56] Gene correction of the apolipoprotein (apo) E2 phenotype to wild-type apoE3 by in situ chimeraplasty
    Tagalakis, AD
    Graham, IR
    Riddell, DR
    Dickson, JG
    Owen, JS
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (16) : 13226 - 13230
  • [57] Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice
    Tsukamoto, K
    Tangirala, R
    Chun, SH
    Puré, E
    Rader, DJ
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (09) : 2162 - 2170
  • [58] Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice
    Tsukamoto, K
    Smith, P
    Glick, JM
    Rader, DJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (01) : 107 - 114
  • [59] VONECKARDSTEIN A, 1996, CURR OPIN LIPIDOL, V7, P89
  • [60] Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver
    Wang, LL
    Nichols, TC
    Read, MS
    Bellinger, DA
    Verma, IM
    [J]. MOLECULAR THERAPY, 2000, 1 (02) : 154 - 158